Skip to main navigation
logo
Contact Us
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Tech
    • Vorolanib
    • DURASERT® Technology
    • VERISOME® Technology
    • Partnerships and BD Initiatives
  • Pipeline & Data
    • Pipeline
    • EYP-1901
      • Overview
      • Clinical Trials
      • Scientific Publications and Presentations
    • EYP-2301
  • Investors
    • Financial Information
      • Financials Overview
      • Stock Information
      • Analyst Coverage
      • Ownership Summary
      • Annual Reports
      • Earnings Releases
      • SEC Filings
    • Resources
      • Press Releases
      • Events & Presentations
      • IR Contact
      • E-mail Alerts
    • Corporate Governance
      • Governance Overview
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • FAQs
    • Form 8937
  • News
  • Careers
Menu
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Tech
    • Vorolanib
    • DURASERT® Technology
    • VERISOME® Technology
    • Partnerships and BD Initiatives
  • Pipeline & Data
    • Pipeline
    • EYP-1901
      • Overview
      • Clinical Trials
      • Scientific Publications and Presentations
    • EYP-2301
  • Investors
    • Financial Information
      • Financials Overview
      • Stock Information
      • Analyst Coverage
      • Ownership Summary
      • Annual Reports
      • Earnings Releases
      • SEC Filings
    • Resources
      • Press Releases
      • Events & Presentations
      • IR Contact
      • E-mail Alerts
    • Corporate Governance
      • Governance Overview
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • FAQs
    • Form 8937
  • News
  • Careers
Menu
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science & Tech
    • Vorolanib
    • DURASERT® Technology
    • VERISOME® Technology
    • Partnerships and BD Initiatives
  • Pipeline & Data
    • Pipeline
    • EYP-1901
      • Overview
      • Clinical Trials
      • Scientific Publications and Presentations
    • EYP-2301
  • Investors
    • Financial Information
      • Financials Overview
      • Stock Information
      • Analyst Coverage
      • Ownership Summary
      • Annual Reports
      • Earnings Releases
      • SEC Filings
    • Resources
      • Press Releases
      • Events & Presentations
      • IR Contact
      • E-mail Alerts
    • Corporate Governance
      • Governance Overview
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • FAQs
    • Form 8937
  • News
  • Careers

SEC Filing Details

  • Financial Information
    • Financials Overview
    • Stock Information
    • Analyst Coverage
    • Ownership Summary
    • Annual Reports
    • Earnings Releases
    • SEC Filings
  • Resources
    • Press Releases
    • Events & Presentations
    • IR Contact
    • E-mail Alerts
  • Corporate Governance
    • Governance Overview
    • Management Team
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • FAQs
  • Form 8937

Document Details

Form
EFFECT
Filing Date
Oct 30, 2023
Document Date
Oct 30, 2023
Form Description
EFFECT
Filing Group
Other
Company
EyePoint Pharmaceuticals
Issuer
EYEPOINT PHARMACEUTICALS, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
  • Print Page
  • Email Alerts
  • RSS News Feeds
  • Home
  • About
  • Science & Tech
  • Pipeline & Data
  • Investors
  • News
  • Careers
  • Contact Us
  • Sitemap
  • Terms and Conditions
  • Privacy Policy
  • Patent Notification
Menu
  • Home
  • About
  • Science & Tech
  • Pipeline & Data
  • Investors
  • News
  • Careers
  • Contact Us
  • Sitemap
  • Terms and Conditions
  • Privacy Policy
  • Patent Notification
EyePoint Logo

EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018- EyePoint Pharmaceuticals, Inc. All Rights Reserved.

 
Linkedin
Facebook
Twitter